Clinical Observation of mXELIRI and mFOLFIRI Combined with Cetuximab in First-line Treatment of Metastatic Left-side Colon Cancer

CHENG Jianping; ZHAO Xiaolin; LI Zhen; YANG Mengyuan; CAO Shichang; YU Jiufei

doi:10.3971/j.issn.1000-8578.2020.19.1475

CHENG Jianping, ZHAO Xiaolin, LI Zhen, YANG Mengyuan, CAO Shichang, YU Jiufei. Clinical Observation of mXELIRI and mFOLFIRI Combined with Cetuximab in First-line Treatment of Metastatic Left-side Colon Cancer[J]. Cancer Research on Prevention and Treatment, 2020, 47(7): 542-546. DOI: 10.3971/j.issn.1000-8578.2020.19.1475

Citation:

Clinical Observation of mXELIRI and mFOLFIRI Combined with Cetuximab in First-line Treatment of Metastatic Left-side Colon Cancer

Graphical Abstract

Abstract

Abstract

Objective To compare the clinical efficacy and safety between mXELIRI and mFOLFIRI combined with cetuximab in the first-line treatment of metastatic left-side colorectal cancer.
Methods We retrospectively analyzed the clinical data of 68 patients with metastatic left-side colorectal cancer treated with cetuximab combined with mXELIRI or mFOLFIRI. We compared the objective response rate (ORR), disease control rate (DCR) and progression-free survival time (PFS) between two regimens, and evaluated the safety.
Results The ORR of mXELIRI and mFOLFIRI groups were 62.5% and 58.4%, the DCR were 87.5% and 88.9%, and the median PFS were 10.5 and 9.9 months, respectively (all P > 0.05). The incidence of hand-foot syndrome (HFS) of mXELIRI group was significantly higher than that of mFOLFIRI group (37.5% vs. 13.9%, P=0.025).
Conclusion Cetuximab combined with mXELIRI and mFOLFIRI in the first-line treatment of metastatic left-side colorectal cancer have equivalent efficacy and safety.

FullText(HTML)

References (21)

Supplements (0)

Cited By

Turn off MathJax

Article Contents

Clinical Observation of mXELIRI and mFOLFIRI Combined with Cetuximab in First-line Treatment of Metastatic Left-side Colon Cancer

Abstract

Catalog

Export File

Citation

Format

Content